UBS Maintains a 'Neutral' on Forest Labs (FRX); Lowers PT and Adjusts Model Based on Rx Trends
More News related to FRX
- Needham & Company maintains a 'Hold' on Forest Labs (FRX); Ceftaroline Panel Is A Blow-Out As AdCom Votes To Approve in Both cSSSI & CABP Indications
- Forest Labs (FRX) Gets Two Positive Votes from FDA Committee's for Ceftaroline Fosamil
- FDA Advisory Committee Recommends Approval of Forest Laboratories’ Ceftaroline Fosamil for the Treatment of Community Acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections
- FDA Panel Says Forest Labs' (FRX) Ceftaroline for Pneumonia Works and Is Safe
- Notable Analyst Rating Changes 09/02: HPQ, RTP, MPEL, ZUMZ Upgraded; PPL, VALE, CRH, AMPH Downgraded
More News related to Analyst Comments
- Wedbush Previews Best Buy's (BBY) Q2 Earnings: Sees Mobile Strength Offsetting Weakness in Other Electronics
- FBR Capital Maintains an 'Outperform/Top Pick' Rating on PG&E (PCG); Stock Sell Off Could be Overdone
- FBR Capital Maintains an 'Outperform' on Boston Properties (BXP); 510 Madison - The Next Chapter
- Barclays Maintains an 'Equalweight' on Texas Instruments (TXN); Mid Q In-Line, Narrowed Range
- Barclays Reiterates an 'Equalweight' Rating on Amkor Technology (AMKR); Update From the Road
UBS maintains a 'Neutral' on Forest Labs (NYSE: FRX), lowers price target from $34 to $33.
UBS makes no changes in its investment thesis, citing no significant EPS upside as Lexapro slows, but the Company has increased pipeline with Daxas and Linaclotide. UBS also sees higher regulatory risk in primary care pipeline.
To see all the upgrades/downgrades on shares of FRX, visit our Analyst Ratings page.
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products, which require a physician’s prescription.
Create E-mail AlertRelated Categories
Analyst CommentsStocks Mentioned
+0.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
